GlassScriptPhysician profile
Saju Das
NPI 1942589668
$18,025.90
in general payments reported to CMS, 2019-2025
40 companies · $2,589 in 2025
The $2,589 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $1,426 · 2021: $3,878 · 2022: $2,367 · 2023: $2,972 · 2024: $3,441 · 2025: $2,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,001.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,500.56 | 2020-2024 | |
| Novo Nordisk INC | $2,062.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,892.95 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,864.48 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $1,631.24 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $1,412.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $969.35 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $866.99 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $845.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $437.83 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $410.76 | 2019-2024 | Xarelto, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $343.88 | 2021-2025 | |
| Exact Sciences Corporation | $313.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $304.52 | 2022-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $248.20 | 2023-2025 | Freestyle Libre |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saju Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.